News India annuls patent of Novartis' heart disease drug Vymada The patent officer cited lack of novelty, insufficient inventive step, and inadequate disclosure of advantages in the patent application as reasons Shajil Kumar Sep 16, 2025
News Novartis to pay Matchpoint up to $1 billion to develop anti-inflammatory therapies Sarwar Alam Jul 25, 2025